Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Samuel L. Aitken"'
Autor:
Paul A. Carpenter, Michael Boeckh, Roy F. Chemaly, Lara Danziger-Isakov, Samuel L. Aitken, Genovefa A. Papanicolaou, Francisco M. Marty, Morgan Hakki, Marian G. Michaels
Publikováno v:
Transplantation and Cellular Therapy. 27:707-719
The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care
Publikováno v:
Transplant Infectious Disease. 24
Solid organ transplant (SOT) recipients are challenging populations for antimicrobial stewardship interventions due to a variety of reasons, including immunosuppression, consequent risk of opportunistic and donor-derived infections, high rates of inf
Autor:
Jason Yeh, Sairah Ahmed, Vi P Doan, Samuel L. Aitken, Ella J. Ariza-Heredia, Alison M. Gulbis
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:1637-1641
National guidelines recommend antimicrobial prophylaxis for allogeneic stem cell transplant patients during the pre-engraftment period because of increased infection risk during neutropenia. Fluoroquinolones have demonstrated lower rates of bacteremi
Publikováno v:
Principles and Practice of Transplant Infectious Diseases ISBN: 9781493990320
Transplant patients are uniquely predisposed to infections with multidrug-resistant organisms both in the early and late phases after transplantation. Similarly, recipients of stem cell or solid organ allograft show greater susceptibility for often d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f41ff25ad054c23be6713583374001b4
https://doi.org/10.1007/978-1-4939-9034-4_50
https://doi.org/10.1007/978-1-4939-9034-4_50
Autor:
Joseph Sassine, Fareed Khawaja, Victoria Handy, Terri Lynn Shigle, Farnaz Foolad, Samuel L Aitken, Ella Ariza Heredia, Roy F Chemaly
Publikováno v:
Open Forum Infectious Diseases
Background CMV reactivation is one of the most common infections after allogeneic hematopoietic cell transplantation (allo-HCT) and carries considerable morbidity and mortality. Primary prophylaxis with letermovir demonstrated in clinical trials redu
Publikováno v:
Transplant Infectious Disease. 18:634-636
Dramatic, overnight cost increases of important orphan and generic medications have recently come under public and government scrutiny. We highlight the case of aerosolized ribavirin, an important antiviral agent in hematopoietic stem cell transplant
Autor:
Ella J. Ariza-Heredia, Farnaz Foolad, Terri Lynn Shigle, Roy F. Chemaly, Shashank S. Ghantoji, Amrita Prayag, Samuel L. Aitken
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S369-S370
Autor:
Victor E. Mulanovich, Dimpy P. Shah, Roy F. Chemaly, Ella J. Ariza-Heredia, Amrita Prayag, Samuel L. Aitken, Firas El Chaer, Annette Artau, Lynn El Haddad
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S385-S386
Autor:
Victoria Wehr Handy, Terri Lynn Shigle, Roy F. Chemaly, Samuel L. Aitken, Fareed Khawaja, Farnaz Foolad
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S276
Introduction Letermovir (LTV) is the first agent approved for CMV prophylaxis (ppx) in CMV-seropositive allo-HCT recipients. In the phase III study, the use of LTV after transplant through day 100 resulted in significantly less episodes of CMV infect
Autor:
Fareed Khawaja, Victoria Wehr Handy, Terri Lynn Shigle, Farnaz Foolad, Roy F. Chemaly, Samuel L. Aitken
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S275
Introduction and Objectives Letermovir (LTV) is the first agent in the class of anti-CMV viral terminase inhibitors and was recently approved in the U.S. for the prevention of CMV infection in CMV-seropositive allo-HCT recipients. In the phase III st